research USE OF RITLECITINIB FOR THE TREATMENT OF ALOPECIA AREATA
Ritlecitinib effectively treats alopecia areata in patients 12 and older with fewer side effects.
Search
for
Sort by
Research
150-180 / 1000+ results 
research The Risks and Benefits of 5α-Reductase Inhibitors for Prostate-Cancer Prevention
5α-reductase inhibitors may prevent prostate cancer but could also raise the risk of more severe cancers.
research Effect of MK-386, a novel inhibitor of type 1 5 alpha-reductase, alone and in combination with finasteride, on serum dihydrotestosterone concentrations in men
research MP09-16 5-ALPHA REDUCTASE INHIBITORS FOR MALE LOWER URINARY TRACT SYMPTOMS: A COCHRANE SYSTEMATIC REVIEW AND META-ANALYSIS
5-alpha reductase inhibitors slightly reduce urinary symptoms and may lower surgery and acute retention risks in men.
research Effect of 5α-reductase inhibitors on sexual function: New contributions
5-alpha reductase inhibitors increase the risk of sexual dysfunction in patients treating enlarged prostate but not in those treating hair loss.
research Patient Considerations when Using Ritlecitinib for Alopecia Areata in Adolescents: Guidance for the Clinicians
Clinicians should consider individual factors and communicate risks and benefits when prescribing ritlecitinib for adolescent alopecia areata.
research Association Between 5-Alpha Reductase Inhibitor Use and The Risk of Depression: A Meta-Analysis.
Using 5-alpha reductase inhibitors may increase the risk of mild depression.
research Good efficacy achieved by baricitinib in the treatment of anti-MDA5 antibody-positive dermatomyositis with alopecia areata
Baricitinib was effective in treating a patient with dermatomyositis and hair loss.
research Effect of 5α-Reductase Inhibitors on Sexual Function: A Meta-Analysis and Systematic Review of Randomized Controlled Trials
5α-reductase inhibitors increase the risk of sexual dysfunction, especially in men with enlarged prostate.
research New 5?-reductase inhibitors: In vitro and in vivo effects
Four new compounds were more effective than finasteride in treating prostate issues and hair loss, with one being 100 times more active and safe for use.
research 5ARI and PSA: open questions
5ARI treatment improves PSA test accuracy for prostate cancer diagnosis.
research Market Analysis of 5α-Reductase Inhibitor
The market for these drugs is expected to grow.
research Patient Profile and Treatment Characteristics of Early Ritlecitinib Initiators in the US
Ritlecitinib provides new treatment options for diverse alopecia areata patients.
research Rational Design and Synthesis of 4-((1R,2R)-2-Hydroxycyclohexyl)-2(trifluoromethyl)benzonitrile (PF-998425), a Novel, Nonsteroidal Androgen Receptor Antagonist Devoid of Phototoxicity for Dermatological Indications
PF-998425 is a new, effective, and non-phototoxic treatment for skin conditions related to androgens.
research Re: Association of Treatment with 5α-Reductase Inhibitors with Time to Diagnosis and Mortality in Prostate Cancer
Treatment with 5α-reductase inhibitors is linked to a delay in prostate cancer diagnosis and may affect survival rates.
research Sexual, physical, and overall adverse effects in patients treated with 5α-reductase inhibitors: a systematic review and meta-analysis
Medications for hair loss and prostate issues can significantly increase the risk of sexual side effects and other negative symptoms.
research Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS)
These medications for BPH have known risks and may have new side effects.
research 5‐Alpha reductase inhibitor related litigation: A legal database review
Most legal cases about 5α-reductase inhibitors, drugs for hair loss and prostate issues, complain about side effects and delayed cancer diagnosis, with most lawsuits settled out of court.
research LB891 Analysis of breast health outcomes in women on oral 5-alpha reductase inhibitors: A single-center retrospective cohort study
5-alpha reductase inhibitors don't increase breast cancer or benign breast disorder risk in women.
research Design, synthesis and structure-activity relationships studies on steroidal aromatase and 5α-reductase inhibitors as anti-tumors
Modified steroidal inhibitors showed promise in treating hormone-dependent cancers.
research No Increased Cardiovascular Hazard with Oral 5-Alpha-Reductase Inhibitors in Treatment of Androgenetic Alopecia: A TriNetX Retrospective Cohort Study
Oral 5-alpha-reductase inhibitors for hair loss don't increase heart risk.
research Using patient preference to inform ritlecitinib dose selection for alopecia areata treatment
Patients prefer the higher 50 mg dose of ritlecitinib for better hair regrowth despite higher risks.
research Evolution of Ritlecitinib Population Pharmacokinetic Models During Clinical Drug Development
Ritlecitinib shows promise as a versatile treatment for various autoimmune and inflammatory diseases.
research Host-directed FDA-approved drugs with antiviral activity against SARS-CoV-2 identified by hierarchical in silico/in vitro screening methods
Five FDA-approved drugs may help block COVID-19 virus entry.
research Synthesis of avicequinone c and analogs toward the study of 5α-reductase inhibitory activity
2-Hydroxy-1,4-naphthoquinone is a strong 5α-reductase inhibitor.
research Baricitinib: Exploring the Safety Profile for the Treatment of Alopecia Areata
Baricitinib is effective for severe alopecia areata with manageable side effects, mainly upper respiratory infections.
research Risk of age-related macular degeneration in men receiving 5α-reductase inhibitors: a population-based cohort study
Men taking dutasteride may have a higher risk of age-related macular degeneration.
research Cost‐Effectiveness Analysis of Ritlecitinib Compared With No Treatment in Patients With Severe Alopecia Areata in Japan
Ritlecitinib is cost-effective for severe alopecia areata in Japan.
research An update on the use of 5alpha-reductase inhibitors
5alpha-reductase inhibitors help treat hair loss and prostate issues but may cause sexual side effects.
research Treatment of Del(5q) Myelodysplastic Syndrome with All-Trans-Retinoic Acid and Tocopherol-α.
The treatment was not recommended due to limited effectiveness and significant side effects.